The dental professional will assess all the present dentition for early carious demineralization and may provide recommendations to the parents or caregivers the best way to prevent ECC and what actions to take. Studies suggest that children who have attended visits within the first few years of life (an early preventive dental visit) potentially experience less dental related issues and incur lower dental related costs throughout their lives. Treatment
The current standard of care for Severe Early Childhood Caries includes restoration and extraction of carious teeth and, where possible, includes early intervention which includes application of topical fluoride, oral hygiene instructions and education. The initial visit is important as it allows dental professionals to flag unfavourable behaviour or eating habits. This will also allow dental clinician, working in a collaborative team, to perform diagnostic testing to determine the rate and progression of the disease. This is done by performing risk assessment based on the childs age, as well as the social, behavioural, and medical history of the child. Children at low risk may not need any restorative therapy, and frequent visits should be made to detect possible early lesions. Children at moderate risk may require restoration of progressing and cavitated lesions, while white spot and enamel proximal lesions should be treated by preventive techniques and monitored for progression. Children at high risk, however, may require earlier restorative intervention of enamel proximal lesions, as well as intervention of progressing and cavitated lesions to minimize continual caries development.
Premature infants who have been given large amounts of benzyl alcohol (99–405 mg/kg/day) have experienced "gasping syndrome". Although enoxaparin is used to prevent blood clots, pregnancy alone can raise a womans risk of clotting. Side effects
Uncommon (<1%)

In people with unstable angina or non-Q-wave myocardial infarction:
Atrial fibrillation, heart failure, lung edema, pneumonia:  ≥ 0.5%vCommon (>1%)

Thrombocytopenia, i.e. can be associated with heparin-induced thrombocytopenia (0.5-5.0% of persons treated for at least five days)
Elevations in serum aminotransferases: 5.9%-6.1%
In people undergoing abdominal or colorectal surgery:
Bleeding, anemia, ecchymosis: ≥ 2%
In persons undergoing hip or knee replacement:
Fever, nausea, anemia, edema, peripheral edema: ≥ 2%
In persons with severely restricted mobility during acute illness:
Dyspnea, thrombocytopenia, confusion, diarrhea, nausea: ≥ 2%
In people being treated for deep vein thrombosis:
Injection site hemorrhage, injection site pain, hematuria: ≥ 2%Frequency under investigation

Local reactions: local irritation, pain, hematoma, ecchymosis, erythema
Bleeding
Hyperkalemia
Transaminitis
Hemorrhage

Boxed warning
The FDA issued a revision to the boxed warning for enoxaparin in October 2013. The revision recommends exercising caution regarding when spinal catheters are placed and removed in persons taking enoxaparin for spinal puncture or neuroaxial anesthesia. It may be necessary to delay anticoagulant dosing in these persons in order to decrease the risk for spinal or epidural hematomas, which can manifest as permanent or long-term paralysis. Persons at risk for hematomas may present with indwelling epidural catheters, concurrent use of medications that worsen bleeding states such as non-steroidal anti-inflammatory drugs (NSAIDs), or a past medical history of epidural or spinal punctures, spinal injury, or spinal deformations. The FDA recommends that at-risk persons be monitored for bleeding and neurological changes.